US20020065255A1 - Disodium salts, monohydrates, and ethanol solvates for delivering active agents - Google Patents

Disodium salts, monohydrates, and ethanol solvates for delivering active agents Download PDF

Info

Publication number
US20020065255A1
US20020065255A1 US09/962,794 US96279401A US2002065255A1 US 20020065255 A1 US20020065255 A1 US 20020065255A1 US 96279401 A US96279401 A US 96279401A US 2002065255 A1 US2002065255 A1 US 2002065255A1
Authority
US
United States
Prior art keywords
delivery agent
disodium salt
composition
unsubstituted
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/962,794
Other languages
English (en)
Inventor
William Bay
Rajesh Agarwal
Kiran Chaudhary
Shingai Majuru
Michael Goldberg
JoAnne Russo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emisphere Technologies Inc
Original Assignee
Emisphere Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Technologies Inc filed Critical Emisphere Technologies Inc
Priority to US09/962,794 priority Critical patent/US20020065255A1/en
Assigned to EMISPHERE TECHNOLOGIES, INC. reassignment EMISPHERE TECHNOLOGIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MAJURU, SHINGAI, AGARWAL, RAJESH K., BAY, WILLIAM E., GOLDBERG, MICHAEL M., RUSSO, JOANNE P., CHAUDHARY, KIRAN
Publication of US20020065255A1 publication Critical patent/US20020065255A1/en
Priority to US10/615,213 priority patent/US7384982B2/en
Priority to US12/111,750 priority patent/US7659311B2/en
Priority to US12/642,508 priority patent/US8003697B2/en
Priority to US13/053,641 priority patent/US8207227B2/en
Priority to US13/481,310 priority patent/US8658695B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
US09/962,794 1999-04-05 2001-09-24 Disodium salts, monohydrates, and ethanol solvates for delivering active agents Abandoned US20020065255A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US09/962,794 US20020065255A1 (en) 1999-04-05 2001-09-24 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US10/615,213 US7384982B2 (en) 1999-04-05 2003-07-07 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US12/111,750 US7659311B2 (en) 1999-04-05 2008-04-29 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US12/642,508 US8003697B2 (en) 1999-04-05 2009-12-18 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US13/053,641 US8207227B2 (en) 1999-04-05 2011-03-22 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US13/481,310 US8658695B2 (en) 1999-04-05 2012-05-25 Disodium salts, monohydrates, and ethanol solvates for delivering active agents

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12775499P 1999-04-05 1999-04-05
US18614200P 2000-03-01 2000-03-01
US18614300P 2000-03-01 2000-03-01
US19128600P 2000-03-21 2000-03-21
PCT/US2000/009390 WO2000059863A1 (en) 1999-04-05 2000-04-05 Disodium salts, monohydrates, and ethanol solvates
US09/962,794 US20020065255A1 (en) 1999-04-05 2001-09-24 Disodium salts, monohydrates, and ethanol solvates for delivering active agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009390 Continuation WO2000059863A1 (en) 1999-04-05 2000-04-05 Disodium salts, monohydrates, and ethanol solvates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/615,213 Continuation US7384982B2 (en) 1999-04-05 2003-07-07 Disodium salts, monohydrates, and ethanol solvates for delivering active agents

Publications (1)

Publication Number Publication Date
US20020065255A1 true US20020065255A1 (en) 2002-05-30

Family

ID=27494697

Family Applications (6)

Application Number Title Priority Date Filing Date
US09/962,794 Abandoned US20020065255A1 (en) 1999-04-05 2001-09-24 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US10/615,213 Expired - Lifetime US7384982B2 (en) 1999-04-05 2003-07-07 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US12/111,750 Expired - Fee Related US7659311B2 (en) 1999-04-05 2008-04-29 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US12/642,508 Expired - Fee Related US8003697B2 (en) 1999-04-05 2009-12-18 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US13/053,641 Expired - Lifetime US8207227B2 (en) 1999-04-05 2011-03-22 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US13/481,310 Expired - Fee Related US8658695B2 (en) 1999-04-05 2012-05-25 Disodium salts, monohydrates, and ethanol solvates for delivering active agents

Family Applications After (5)

Application Number Title Priority Date Filing Date
US10/615,213 Expired - Lifetime US7384982B2 (en) 1999-04-05 2003-07-07 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US12/111,750 Expired - Fee Related US7659311B2 (en) 1999-04-05 2008-04-29 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US12/642,508 Expired - Fee Related US8003697B2 (en) 1999-04-05 2009-12-18 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US13/053,641 Expired - Lifetime US8207227B2 (en) 1999-04-05 2011-03-22 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US13/481,310 Expired - Fee Related US8658695B2 (en) 1999-04-05 2012-05-25 Disodium salts, monohydrates, and ethanol solvates for delivering active agents

Country Status (12)

Country Link
US (6) US20020065255A1 (US07384982-20080610-C00002.png)
EP (1) EP1175390B1 (US07384982-20080610-C00002.png)
JP (2) JP4588221B2 (US07384982-20080610-C00002.png)
AT (1) ATE288415T1 (US07384982-20080610-C00002.png)
AU (1) AU4216700A (US07384982-20080610-C00002.png)
CA (1) CA2369591C (US07384982-20080610-C00002.png)
DE (1) DE60017888T2 (US07384982-20080610-C00002.png)
ES (1) ES2235854T3 (US07384982-20080610-C00002.png)
HK (1) HK1045680A1 (US07384982-20080610-C00002.png)
IL (4) IL145546A0 (US07384982-20080610-C00002.png)
NZ (1) NZ534409A (US07384982-20080610-C00002.png)
WO (1) WO2000059863A1 (US07384982-20080610-C00002.png)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112937A1 (en) 2004-05-19 2005-12-01 Emisphere Technologies, Inc. Acyclovir formulations
WO2005112943A1 (en) * 2004-05-19 2005-12-01 Emisphere Technologies, Inc. Topical cromolyn formulations
WO2005107462A3 (en) * 2004-05-06 2006-05-04 Emisphere Tech Inc Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US20060135402A1 (en) * 2002-08-01 2006-06-22 Moise Azria Oral administration of calcitonin
WO2006063821A1 (en) * 2004-12-16 2006-06-22 Novartis Ag Manufacture process of n-substituted salicylamides
WO2006072070A2 (en) 2004-12-29 2006-07-06 Emisphere Technologies, Inc. Pharmaceutical formulations of gallium salts
WO2006076692A1 (en) * 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
US20060194722A1 (en) * 2003-07-23 2006-08-31 Moise Azria Use of calcitonin in osteoarthritis
US20070224262A1 (en) * 2004-05-06 2007-09-27 Shingai Majuru Solid Dosage Form of Wetted Heparin
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
US20080146509A1 (en) * 2002-05-09 2008-06-19 Emisphere Technologies, Inc. Compositions for delivering parathyroid hormone and calcitonin
EP1937627A2 (en) * 2005-09-19 2008-07-02 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8-aminocaprylic acid
WO2008003050A3 (en) * 2006-06-28 2009-05-28 Emisphere Tech Inc Gallium nitrate formulations
US20090163408A1 (en) * 2006-08-08 2009-06-25 The Regents Of The University Of California Salicylanilides enhance oral delivery of therapeutic peptides
US20100151009A1 (en) * 2006-04-12 2010-06-17 Emisphere Technologies Inc. Formulations for delivering insulin
US20100210526A1 (en) * 2007-03-02 2010-08-19 Yatindra Joshi Oral administration of a calcitonin
EP2279732A2 (en) 2004-05-14 2011-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1953753B (zh) * 2004-05-06 2011-02-09 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
WO2011017346A2 (en) 2009-08-03 2011-02-10 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
US20110207693A1 (en) * 2010-02-24 2011-08-25 Emisphere Technologies, Inc. Oral B12 Therapy
US20120046224A1 (en) * 2009-03-12 2012-02-23 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
US8288360B2 (en) 2007-11-02 2012-10-16 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
KR101193228B1 (ko) * 2004-05-06 2012-10-22 에미스페어 테크놀로지스, 인코포레이티드 모노소듐 ｎ-［8-(2-히드록시벤조일)아미노］카프릴레이트의 결정 다형 형태
US20130183385A1 (en) * 2011-11-02 2013-07-18 Nu-Co Development Gmbh Peptide analogs for treating diseases and disorders
US8771712B2 (en) 2006-05-09 2014-07-08 Emisphere Technologies, Inc. Topical administration of acyclovir
US20150196617A1 (en) * 2011-11-02 2015-07-16 Keybioscience Ag Peptide Analogs for Treating Diseases and Disorders
US9783513B2 (en) 2012-08-16 2017-10-10 Ohio State Innovation Foundation STAT3 inhibitors and their anticancer use
WO2019071211A1 (en) * 2017-10-05 2019-04-11 Receptor Life Sciences, Inc. HERB COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY
WO2019071213A1 (en) * 2017-10-05 2019-04-11 Receptor Life Sciences, Inc. SYNTHETIC AND PLANT-BASED CANNABINOID FORMULATIONS WITH RAPID EFFECT AND EXTENDED ACTION
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
US11246852B2 (en) 2016-12-02 2022-02-15 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
ES2242412T3 (es) 1998-07-27 2005-11-01 Emisphere Technologies, Inc. Compuestos que permiten administrar agentes activos y composiciones a base de estos compuestos.
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
EP1246792B1 (en) * 2000-01-13 2014-08-13 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
PT1397156E (pt) 2001-06-01 2007-05-31 Novartis Ag Método para a administração oral da hormona paratireóide ( pth ).
PL210258B1 (pl) * 2001-08-17 2011-12-30 Novartis Ag Kompozycja farmaceutyczna do podawania doustnego fragmentów hormonu przytarczyc oraz jej zastosowanie
CA2466863A1 (en) * 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
EP1469827B1 (en) 2002-01-09 2017-12-27 Emisphere Technologies, Inc. Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
TW200403052A (en) 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
CN1809377B (zh) * 2003-07-11 2010-08-04 诺瓦提斯公司 包含微粉化形式的传送剂的口服给药药物组合物
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
EP1658273B1 (en) 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
JP4754487B2 (ja) 2003-08-20 2011-08-24 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド（ｇｌｐ）−１化合物またはメラノコルチン４受容体（ｍｃ４）アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
MXPA06011903A (es) 2004-04-16 2007-03-21 Emisphere Tech Inc 8-(2-hidroxi-fenoxi)-octil-dietanolamida y sales de la misma para el suministro de agentes activos.
RU2530889C2 (ru) * 2004-05-14 2014-10-20 Эмисфире Текнолоджис, Инк. Соединения и составы для доставки активных веществ
AU2005249410A1 (en) 2004-05-14 2005-12-15 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
US9399054B2 (en) * 2004-07-12 2016-07-26 Emisphere Technologies, Inc. Compositions for delivering peptide YY and PYY agonists
CN101014360A (zh) 2004-08-03 2007-08-08 埃米斯菲尔技术公司 抗糖尿病口服胰岛素－双胍组合物
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
US8030271B2 (en) * 2005-07-05 2011-10-04 Emisphere Technologies, Inc. Compositions and methods for buccal delivery of human growth hormone
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CA2626933C (en) 2005-11-17 2015-12-29 Novartis Ag Pharmaceutical composition
WO2008027958A2 (en) 2006-08-31 2008-03-06 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP5042312B2 (ja) * 2006-08-31 2012-10-03 ノバルティス アーゲー Ｈｇｈを含む経口送達用医薬組成物
US10875826B2 (en) * 2006-09-07 2020-12-29 Emisphere Technologies, Inc. Process for the manufacture of SNAC (salcaprozate sodium)
PL3050568T3 (pl) 2007-03-13 2021-06-14 Jds Therapeutics, Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
EP2185136A2 (en) 2007-08-09 2010-05-19 Novartis Ag Oral calcitonin compositions and applications thereof
EP2676956A1 (en) * 2008-08-01 2013-12-25 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
ES2626327T3 (es) 2009-02-06 2017-07-24 The Regents Of The University Of California Agentes enlazantes de calcio que inducen crecimiento del cabello y/o crecimiento de las uñas
KR101811376B1 (ko) * 2010-06-09 2017-12-22 에미스페어 테크놀로지스, 인코포레이티드 경구용 철 결핍증 치료
EP2605655B1 (en) 2010-08-19 2018-10-24 Buck Institute for Age Research Methods of treating mild cognitive impairment (mci) and related disorders
CA2809363A1 (en) 2010-08-24 2012-03-01 Abbott Laboratories Hiv core protein specific antibodies and uses thereof
CA2823628A1 (en) 2011-01-05 2012-07-12 Hospira, Inc. Spray drying vancomycin
MX344925B (es) 2011-03-01 2017-01-11 N21 Acquisition Holding Llc Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas.
PT3095484T (pt) 2011-11-02 2018-06-20 Keybioscience Ag Miméticas de calcitonina para tratar doenças e distúrbios
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
AU2013318338B2 (en) 2012-09-21 2017-05-25 Intensity Therapeutics, Inc Method of treating cancer
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
CA2918052A1 (en) 2013-07-12 2015-01-15 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
PL3321278T3 (pl) 2013-11-14 2019-06-28 Keybioscience Ag Mimetyki kalcytoniny do leczenia chorób i zaburzeń
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
WO2016061144A1 (en) 2014-10-14 2016-04-21 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
EP3256113A4 (en) * 2015-02-09 2018-11-14 Entera Bio Ltd. Treatment of hypoparathyroidism
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
AU2017217466A1 (en) 2016-02-11 2018-08-23 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
AU2018205458A1 (en) 2017-01-05 2019-07-11 The Regents Of The University Of California PAC1 receptor agonists (MAXCAPS) and uses thereof
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
WO2019083904A1 (en) 2017-10-23 2019-05-02 Chan Zuckerberg Biohub, Inc. AFUCOSYLATED IGG FC GLYCANES MEASUREMENT AND METHODS OF TREATMENT THEREOF
US20210087250A1 (en) 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
CN111057165A (zh) * 2020-01-13 2020-04-24 苏州健飞肠衣有限公司 一种高纯度肝素钠的制备方法
WO2022049310A1 (en) 2020-09-07 2022-03-10 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
US11667614B2 (en) 2021-04-16 2023-06-06 Navinta III Inc. Process for the preparation of highly pure Salcaprozic Acid and pharmaceutically acceptable salts thereof
EP4323330A1 (en) 2021-04-16 2024-02-21 Navinta III Inc Process for the preparation of highly pure salcaprozic acid and pharmaceutically acceptable salts thereof
IL307875A (en) 2021-04-22 2023-12-01 Civi Biopharma Inc Oral administration of oligonucleotides
AU2022311059A1 (en) 2021-07-16 2024-01-18 Novo Nordisk A/S Sodium n-(8-(2- hydroxybenzoyl)amino)caprylate polymorphic form a
WO2023166179A1 (en) 2022-03-03 2023-09-07 Cyprumed Gmbh Improved oral pharmaceutical formulations of therapeutic peptides and proteins

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES369853A1 (es) * 1969-07-24 1971-07-16 Bama S A Lab Procedimiento para la obtencion de derivados del acido ep- silon-amino-caproico.
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
US4061466A (en) * 1974-10-16 1977-12-06 Ingvar Gosta Holger Sjoholm Biologically active composition and the use thereof
DE2500157C2 (de) * 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
DE2517229A1 (de) * 1975-04-18 1976-10-28 Boehringer Mannheim Gmbh Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
DE2532420A1 (de) * 1975-07-19 1977-02-03 Boehringer Mannheim Gmbh Phenylessigsaeure-derivate und verfahren zu ihrer herstellung
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
NZ196349A (en) * 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
US4442090A (en) * 1980-11-09 1984-04-10 Kyoto Yakuhin Kogyo Kabushiki Kaisha Absorption-promoting compounds, compositions thereof with pharmaceuticals and/or bases for rectal administration and method of use
US4900730A (en) * 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
GB2092136B (en) * 1981-01-17 1985-06-05 Mitsui Toatsu Chemicals Production of n-substituted amide compounds
FR2509175B1 (fr) 1981-03-06 1987-01-16 Toyo Jozo Kk Preparation therapeutique ayant d'excellentes proprietes d'absorption
JPS58140026A (ja) * 1982-01-14 1983-08-19 Toyo Jozo Co Ltd 吸収性良好な製剤
US4499299A (en) * 1981-12-30 1985-02-12 Ici Americas Inc. Pharmaceutically active phenylcarboxylic acid derivatives
US4654327A (en) * 1982-04-21 1987-03-31 Research Corp. Quaternary ammonium complexes of heparin
US4393192A (en) * 1982-12-21 1983-07-12 The Standard Oil Company Crystalline copolymers prepared from N,N'-terephthaloyldi-beta-alanine and a glycol
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US4898729A (en) * 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4757066A (en) * 1984-10-15 1988-07-12 Sankyo Company Limited Composition containing a penem or carbapenem antibiotic and the use of the same
CA1234561A (en) 1985-06-26 1988-03-29 Kenneth M. White Profiled body roller-reamer stabilizer
IL77186A0 (en) 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
US4689182A (en) 1985-12-20 1987-08-25 Warner-Lambert Company Benzoic acid and benzoic acid ester derivatives having anti-inflammatory and analgesic activity
LU86258A1 (fr) * 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
USRE35862E (en) * 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
JPH0725725B2 (ja) * 1987-07-23 1995-03-22 保土谷化学工業株式会社 ベンズアミド誘導体
FR2636238B1 (fr) * 1988-09-14 1994-01-21 Morelle Jean Nouvelles compositions antisudorales
GB8823731D0 (en) 1988-10-10 1988-11-16 Smith Kline French Lab Biologically active compounds
FR2639395B1 (fr) 1988-11-18 1991-02-15 Rockwell Cim Dispositif d'accouplement entre une vitre et un mecanisme de leve-vitre a bras oscillants dans un vehicule automobile
JPH02239980A (ja) 1989-03-15 1990-09-21 Fuji Photo Film Co Ltd 感熱記録材料
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5451410A (en) * 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6221367B1 (en) * 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
HU211995B (en) 1992-06-30 1996-01-29 Gyogyszerkutato Intezet Process to prepare novel benzoyl amino acid derivs. and pharmaceutical compns. contg.them
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU6819294A (en) * 1993-04-22 1994-11-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1151836C (zh) * 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) * 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6051258A (en) 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
SI9720025A (sl) * 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
GB2314189B (en) 1996-06-14 2000-08-09 Mars Inc Coin handling apparatus
US6060513A (en) * 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5804688A (en) * 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5939381A (en) * 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6051561A (en) * 1997-02-07 2000-04-18 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5876710A (en) * 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
CA2279331C (en) * 1997-02-07 2010-04-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5776888A (en) * 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) * 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5879681A (en) * 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CO5021171A1 (es) * 1997-12-08 2001-03-27 Smithkline Beechman Corp Sal de monoargininilo del acido(e)-3-(1-n-butil-5-(2-(2- carboxifenil)metoxi-4-clorofenil)-1h-pirazol-4-il)-2- ((5-metoxi-2,3-dihidrobenzofuran-5-il)metil)-prop-2-enoico
ES2242412T3 (es) 1998-07-27 2005-11-01 Emisphere Technologies, Inc. Compuestos que permiten administrar agentes activos y composiciones a base de estos compuestos.
WO2000007979A2 (en) 1998-08-07 2000-02-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6066015A (en) 1998-08-17 2000-05-23 Brown; James D. Method and system for anchoring a buoy via a screw-type anchor
AU3240900A (en) 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
KR101413055B1 (ko) 2005-08-25 2014-07-02 아리조나 보드 오브 리전츠 온 비해프 오브 더 유니버시티 오브 아리조나 발암의 줄기세포 융합 모델
US20070048725A1 (en) 2005-08-25 2007-03-01 Arrington Ben O'mar Machine perfusion of tissue grafts for transplantation
WO2011048589A2 (en) 2009-10-23 2011-04-28 Ben Gurion University Of The Negev Research And Development Authority Ion exchangers and methods of use thereof

Cited By (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US20080146509A1 (en) * 2002-05-09 2008-06-19 Emisphere Technologies, Inc. Compositions for delivering parathyroid hormone and calcitonin
US20090264368A1 (en) * 2002-05-09 2009-10-22 Emisphere Technologies, Inc. Compositions for delivering parathyroid hormone and calcitonin
US20060135402A1 (en) * 2002-08-01 2006-06-22 Moise Azria Oral administration of calcitonin
US7569539B2 (en) 2002-08-01 2009-08-04 Novartis Ag Oral administration of calcitonin
US20140271735A1 (en) * 2003-07-23 2014-09-18 Novartis Ag Use of calcitonin in osteoarthritis
US8765675B2 (en) * 2003-07-23 2014-07-01 Novartis Ag Use of calcitonin in osteoarthritis
US20100278881A1 (en) * 2003-07-23 2010-11-04 Novartis Ag Use of calcitonin in osteoarthritis
US7749954B2 (en) * 2003-07-23 2010-07-06 Novartis Ag Use of calcitonin in osteoarthritis
US20060194722A1 (en) * 2003-07-23 2006-08-31 Moise Azria Use of calcitonin in osteoarthritis
AU2005240213A8 (en) * 2004-05-06 2011-10-20 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
US11395809B2 (en) 2004-05-06 2022-07-26 Novo Nordisk North America Operations A/S Crystalline polymorphic forms of monosodium n-[-8-(2-hydroxybenzoyl)amino]caprylate
US9321719B2 (en) 2004-05-06 2016-04-26 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium N-[-8-(2-hydroxybenzoyl)amino]caprylate
AU2005240213B8 (en) * 2004-05-06 2011-10-20 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
WO2005107462A3 (en) * 2004-05-06 2006-05-04 Emisphere Tech Inc Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
US8636996B2 (en) * 2004-05-06 2014-01-28 Emisphere Technologies, Inc Crystalline polymorphic forms of monosodium N-[-8-(2-hydroxybenzoyl)amino]caprylate
US8039018B2 (en) 2004-05-06 2011-10-18 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
AU2005240213B2 (en) * 2004-05-06 2011-09-22 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
US20090143330A1 (en) * 2004-05-06 2009-06-04 Emisphere Technologies, Inc. Crystalline Polymorphic Forms Of Monosodium N-[-8-(2-Hydroxybenzoyl)Amino]Caprylate
US9750710B2 (en) 2004-05-06 2017-09-05 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium N-[-8-(2-hydroxybenzoyl)amino]caprylate
US20070224262A1 (en) * 2004-05-06 2007-09-27 Shingai Majuru Solid Dosage Form of Wetted Heparin
EP3058944A1 (en) * 2004-05-06 2016-08-24 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
US10188621B2 (en) 2004-05-06 2019-01-29 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium N-[-8-(2-hydroxybenzoyl)amino]caprylate
KR101193228B1 (ko) * 2004-05-06 2012-10-22 에미스페어 테크놀로지스, 인코포레이티드 모노소듐 ｎ-［8-(2-히드록시벤조일)아미노］카프릴레이트의 결정 다형 형태
EA013518B1 (ru) * 2004-05-06 2010-06-30 Эмисфире Текнолоджис, Инк. Кристаллические полиморфные формы n-[8-(2-гидроксибензоил)амино]каприлата натрия
EP3572086A1 (en) * 2004-05-06 2019-11-27 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
US10744105B2 (en) 2004-05-06 2020-08-18 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium N-[-8-(2-hydroxybenzoyl)amino]caprylate
CN102040535B (zh) * 2004-05-06 2012-10-17 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
CN1953753B (zh) * 2004-05-06 2011-02-09 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
EP2279732A2 (en) 2004-05-14 2011-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1968704B (zh) * 2004-05-19 2010-12-08 爱密斯菲尔科技公司 局部用色甘酸制剂
AU2005244986B2 (en) * 2004-05-19 2011-01-27 Emisphere Technologies, Inc. Topical cromolyn formulations
AU2011201896B2 (en) * 2004-05-19 2012-03-15 Emisphere Technologies, Inc. Topical cromolyn formulations
WO2005112943A1 (en) * 2004-05-19 2005-12-01 Emisphere Technologies, Inc. Topical cromolyn formulations
WO2005112937A1 (en) 2004-05-19 2005-12-01 Emisphere Technologies, Inc. Acyclovir formulations
WO2006063821A1 (en) * 2004-12-16 2006-06-22 Novartis Ag Manufacture process of n-substituted salicylamides
NO338969B1 (no) * 2004-12-16 2016-11-07 Novartis Ag Fremgangsmåte for fremstilling av N-substituerte salisylamider
EP2955171A1 (en) 2004-12-16 2015-12-16 Novartis AG Manufacture process of n-(5-chlorosalicyloyl)-8-aminocaprylic acid
AU2005315850B2 (en) * 2004-12-16 2009-11-05 Novartis Ag Manufacture process of N-substituted salicylamides
US8461385B2 (en) 2004-12-16 2013-06-11 Novartis Ag Manufacture process of organic compounds
KR101287233B1 (ko) 2004-12-16 2013-07-17 노파르티스 아게 Ｎ-치환된 살리실아미드의 제조 방법
WO2006072070A2 (en) 2004-12-29 2006-07-06 Emisphere Technologies, Inc. Pharmaceutical formulations of gallium salts
US9345725B2 (en) * 2004-12-29 2016-05-24 Emisphere Technologies, Inc. Pharmaceutical formulations of gallium salts
US20090123562A1 (en) * 2004-12-29 2009-05-14 Emisphere Technologies, Inc. Pharmaceutical Formulations of Gallium Salts
US8110547B2 (en) * 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
US20080200380A1 (en) * 2005-01-12 2008-08-21 Emisphere Technologies, Inc. Compositions For Buccal Delivery Of Parathyroid Hormone
WO2006076692A1 (en) * 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
AU2006292337B2 (en) * 2005-09-19 2012-11-01 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
US20080269108A1 (en) * 2005-09-19 2008-10-30 Emisphere Technologies, Inc. Crystalline forms of the Di-Sodium Salt of N-(5-Chlorosalicyloyl)-8-Aminocaprylic Acid
AU2006292337B8 (en) * 2005-09-19 2013-02-07 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
EP1937627A4 (en) * 2005-09-19 2010-09-01 Emisphere Tech Inc CRYSTALLINE FORMS OF N-(5-CHLOROSALICYLOYL) -8-AMINOCAPRYL ACETATE
US8431736B2 (en) 2005-09-19 2013-04-30 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
EP1937627A2 (en) * 2005-09-19 2008-07-02 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8-aminocaprylic acid
US9238074B2 (en) 2005-09-19 2016-01-19 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
US8026392B2 (en) * 2005-09-19 2011-09-27 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-Chlorosalicyloyl)-8-aminocaprylic acid
JP2009508875A (ja) * 2005-09-19 2009-03-05 エミスフェアー・テクノロジーズ・インク Ｎ−（５−クロロサリチロイル）−８−アミノカプリル酸二ナトリウム塩の結晶形
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
US20100151009A1 (en) * 2006-04-12 2010-06-17 Emisphere Technologies Inc. Formulations for delivering insulin
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
US8771712B2 (en) 2006-05-09 2014-07-08 Emisphere Technologies, Inc. Topical administration of acyclovir
US9364502B2 (en) 2006-06-28 2016-06-14 Emisphere Technologies, Inc. Gallium nitrate formulations
WO2008003050A3 (en) * 2006-06-28 2009-05-28 Emisphere Tech Inc Gallium nitrate formulations
US20100239658A1 (en) * 2006-06-28 2010-09-23 Emisphere Technologies, Inc. Gallium nitrate formulations
US8148328B2 (en) 2006-08-08 2012-04-03 The Regents Of The University Of California Salicylanilides enhance oral delivery of therapeutic peptides
US20090163408A1 (en) * 2006-08-08 2009-06-25 The Regents Of The University Of California Salicylanilides enhance oral delivery of therapeutic peptides
US20100210526A1 (en) * 2007-03-02 2010-08-19 Yatindra Joshi Oral administration of a calcitonin
US8410052B2 (en) 2007-03-02 2013-04-02 Novartis Ag Oral administration of a calcitonin
US8557792B2 (en) 2007-11-02 2013-10-15 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
US8288360B2 (en) 2007-11-02 2012-10-16 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
US20120046224A1 (en) * 2009-03-12 2012-02-23 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
WO2011017346A2 (en) 2009-08-03 2011-02-10 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
US20110207693A1 (en) * 2010-02-24 2011-08-25 Emisphere Technologies, Inc. Oral B12 Therapy
US9533022B2 (en) * 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
US20150196617A1 (en) * 2011-11-02 2015-07-16 Keybioscience Ag Peptide Analogs for Treating Diseases and Disorders
US20130183385A1 (en) * 2011-11-02 2013-07-18 Nu-Co Development Gmbh Peptide analogs for treating diseases and disorders
US9006172B2 (en) * 2011-11-02 2015-04-14 Keybioscience Ag Peptide analogs for treating diseases and disorders
US9783513B2 (en) 2012-08-16 2017-10-10 Ohio State Innovation Foundation STAT3 inhibitors and their anticancer use
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
US11129897B2 (en) 2016-04-22 2021-09-28 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
US11246852B2 (en) 2016-12-02 2022-02-15 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
WO2019071211A1 (en) * 2017-10-05 2019-04-11 Receptor Life Sciences, Inc. HERB COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY
WO2019071213A1 (en) * 2017-10-05 2019-04-11 Receptor Life Sciences, Inc. SYNTHETIC AND PLANT-BASED CANNABINOID FORMULATIONS WITH RAPID EFFECT AND EXTENDED ACTION

Also Published As

Publication number Publication date
US7384982B2 (en) 2008-06-10
US20080269134A1 (en) 2008-10-30
EP1175390A1 (en) 2002-01-30
EP1175390A4 (en) 2002-09-04
EP1175390B1 (en) 2005-02-02
ATE288415T1 (de) 2005-02-15
JP2005068161A (ja) 2005-03-17
US20040106825A1 (en) 2004-06-03
DE60017888D1 (de) 2005-03-10
JP2002541132A (ja) 2002-12-03
US20120264834A1 (en) 2012-10-18
US20110251125A1 (en) 2011-10-13
US8658695B2 (en) 2014-02-25
IL145546A0 (en) 2002-06-30
AU4216700A (en) 2000-10-23
CA2369591C (en) 2011-06-14
HK1045680A1 (en) 2002-12-06
US8207227B2 (en) 2012-06-26
NZ534409A (en) 2006-03-31
WO2000059863A1 (en) 2000-10-12
US8003697B2 (en) 2011-08-23
CA2369591A1 (en) 2000-10-12
JP4588221B2 (ja) 2010-11-24
IL166158A (en) 2010-12-30
DE60017888T2 (de) 2006-01-19
IL166158A0 (en) 2006-01-15
IL180118A0 (en) 2007-06-03
JP4642435B2 (ja) 2011-03-02
IL180118A (en) 2010-12-30
US7659311B2 (en) 2010-02-09
IL145546A (en) 2007-10-31
ES2235854T3 (es) 2005-07-16
US20100099621A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
US8658695B2 (en) Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US7208178B2 (en) Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
EP3572086B1 (en) Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
US20040048777A1 (en) Compounds and compositions for delivering active agents
WO2001032130A2 (en) Phenyl amine carboxylic acid compounds and compositions for delivering active agents
AU2001273153A1 (en) Compounds and compositions for delivering active agents
WO2000059480A1 (en) Lyophilized solid dosage forms and methods of making
US7129274B1 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
EP1535625A1 (en) Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
AU2004201690B2 (en) Disodium salts, monohydrates, and ethanol solvates for delivering active agents
AU2005200367B2 (en) Disodium salts, monohydrates, and ethanol solvates for delivering active agents
NZ535896A (en) Disodium salts, monohydrates, and ethanol solvates for delivering active agents
CA2487952A1 (en) Disodium salts, monohydrates, and ethanol solvates for delivering active agents

Legal Events

Date Code Title Description
AS Assignment

Owner name: EMISPHERE TECHNOLOGIES, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAY, WILLIAM E.;AGARWAL, RAJESH K.;CHAUDHARY, KIRAN;AND OTHERS;REEL/FRAME:012378/0316;SIGNING DATES FROM 20011010 TO 20011017

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE